drugset / Trial / NCT05618366
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1
Terminated
3 enrolled
Weill Medical College of Cornell University
Epizyme, Inc. · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venetoclax to give with tazemetostat to people with R/R NHL; what types of side effects do people with R/R NHL get when taking venetoclax with tazemetostat; and what effects does this combination have on R/R NHL. Participants will need to take pills by mouth every day and regularly come to the clinic for blood work and imagining to monitor side effects and cancer progression. Participants may receive study drugs for up to 24 months.
Timeline
- Start
- 2023-06-07
- Primary completion
- 2026-02-27
- Completion
- 2026-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |